.jpeg)
2026-03-11 07:15:54
Repotrectinib, as a next-generation ROS1/NTRK tyrosine kinase inhibitor, has attracted significant attention regarding its generational classification. This article professionally analyzes Repotrectinib's generation positioning, core characteristics, and treatment sequence based on the development history of ROS1 inhibitors.
2026-03-10 01:38:34
Goserelin, as a GnRH analog, is widely used for prostate cancer, breast cancer, and gynecological diseases, but may cause side effects like hot flashes and bone density loss. 2025 clinical guidelines recommend light, nutritious, balanced diet with high protein and calcium, avoiding spicy and processed foods. Special populations need personalized management to enhance treatment tolerance and quality of life.
2026-03-10 01:22:25
Breakthrough research published in "Genes & Immunity" (2025) identifies folate metabolism-related gene CYP26A1 as a clinical immune target for colorectal cancer. Multi-omics analysis and experimental validation reveal CYP26A1's role in promoting tumor proliferation, metastasis, and immunosuppressive microenvironment, offering new precision treatment directions for patients.
2026-03-06 05:41:28
Decoding Inavolisib’s breakthrough in PIK3CA-mutant HR+/HER2- breast cancer: INAVO120 trial data, quality-of-life preservation, and expansion to HER2+ disease.
2026-02-28 06:38:41
Master Regorafenib (Stivarga) dosing: low-fat breakfast, fixed timing, dose escalation strategy for optimal efficacy and reduced side effects in liver and colorectal cancer.
2026-02-26 03:14:05
Erlotinib,also known as Tarceva,is a classic drug of the epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)family and has a milestone in the precision treatment of lung cancer.Its core indication is non-small cell lung cancer(NSCLC)patients carrying EGFR sensitive mutations.With the advantages of precise targeting and definite efficacy,it effectively breaks the limitations of traditional chemotherapy,promotes the new era of lung cancer treatment from"extensive chemotherapy"to"precise targeting",and brings longer survival and better quality of life to countless advanced lung cancer patients.
2026-01-26 06:00:27
Ibrutinib (generic name: Ibrutinib) is a targeted therapy prescription drug that exerts therapeutic effects by inhibiting Bruton's tyrosine kinase (BTK).
2026-01-21 02:04:41
Palisib (brand name: IBRANCE) is the world's first commercially available CDK4/6 kinase inhibitor, approved by the US FDA through the accelerated approval pathway on February 3, 2015. Developed by Pfizer, this drug is indicated for use in combination with letrozole in the treatment of postmenopausal women with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as an initial endocrine therapy regimen. Its approval is based on clinical data demonstrating a significant prolongation of progression-free survival (PFS), marking an important advancement in the treatment of hormone receptor-positive advanced breast cancer.
2026-01-19 06:07:42
Pralsetinib is a revolutionary high-selectivity RET inhibitor, precisely designed for the treatment of lung and thyroid cancers harboring RET gene mutations. With superior efficacy compared to traditional therapies and enhanced safety profile, it has delivered breakthrough survival benefits for patients with these rare mutations, establishing itself as the new standard of care.
2026-01-15 06:18:33
On October 24,2025,Syndax Pharmaceuticals announced that the U.S.Food and Drug Administration(FDA)has approved Revuforj(revumenib)for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory(R/R)acute myeloid leukemia(AML)carrying nucleolar phosphoprotein 1(NPM1)mutations and for whom there are no suitable alternative treatment options.Revuforj was previously approved in 2024 for the treatment of adult and pediatric patients aged 1 year and older with R/R acute leukemia associated with a lysine methyltransferase 2A gene(KMT2A)translocation.
